Biotech Investing Glossary: Clinical Trial, FDA and Stock Terms Explained

Biotech investing has its own language. Trial results are often reported using terms such as mOS, PFS, hazard ratio, p-value, interim analysis, control arm, BLA, PDUFA, dilution and cash runway. For experienced biotech investors, these terms are routine. For newer investors, they can make a company update sound far more certain — or far more confusing — than it really is.

This glossary explains the most important biotech investing terms in plain English. The goal is not to turn every reader into a statistician or oncologist. The goal is to help investors read clinical trial updates, press releases and SEC filings with more confidence.

Many biotech stock moves happen around a small number of catalysts: clinical trial readouts, FDA decisions, financing events, partnership announcements or safety updates. Understanding the terms behind those catalysts can help investors avoid common mistakes, such as confusing pooled survival data with treatment-arm survival, mistaking “median not reached” for proof of success, or ignoring dilution when modeling upside.

Clinical trial endpoints

mOS — median overall survival

Median overall survival, or mOS, is the time point at which half of the patients in a study group have died and half are still alive. In cancer trials, mOS is one of the most important survival endpoints because it measures whether patients live longer.

However, mOS is often misunderstood. It is not the average survival time. It also does not always tell the full story if the trial is immature, heavily censored or still blinded.

Median not reached

“Median not reached” means that fewer than half of the patients in a group have had the event being measured, such as death or disease progression. It can be encouraging, but it does not automatically prove that a drug works.

In a blinded trial, pooled median survival not being reached does not mean the experimental arm’s median survival has not been reached.

OS — overall survival

Overall survival measures the time from a defined starting point, such as randomization or treatment start, until death from any cause. OS is considered one of the hardest and most meaningful endpoints in oncology because it measures whether patients live longer.

PFS — progression-free survival

Progression-free survival measures how long patients live without the disease getting worse. PFS can be reached faster than OS, which makes trials shorter. However, PFS is often more subjective than OS because it depends on scans, assessment timing and definitions of progression.

ORR — objective response rate

Objective response rate is the percentage of patients whose tumors shrink by a predefined amount. ORR is often used in solid tumor studies, especially in earlier-stage trials.

DCR — disease control rate

Disease control rate includes patients with tumor shrinkage plus patients whose disease remains stable. DCR can sound impressive, but it is weaker than ORR if most of the benefit comes from stable disease rather than actual tumor shrinkage.

DoR — duration of response

Duration of response measures how long a response lasts after a patient responds to therapy. A high ORR with short DoR may be less valuable than a lower ORR with long-lasting responses.

Survival analysis terms

Hazard ratio

Hazard ratio, or HR, compares the risk of an event between two groups over time. An HR below 1 favors the experimental treatment. For example, an HR of 0.70 suggests a 30% lower risk of the event compared with the control arm.

Kaplan-Meier curve

A Kaplan-Meier curve is a survival graph showing the percentage of patients who remain alive or progression-free over time. It can reveal early benefit, delayed benefit, curve crossing or a long survival tail.

Censoring

Censoring happens when a patient has not yet had the event by the time of analysis, leaves the study, or is lost to follow-up. Censoring is normal in clinical trials, but heavy or imbalanced censoring can make results harder to interpret.

P-value

A p-value helps estimate whether a result could have occurred by chance. In many pivotal trials, a p-value below 0.05 is considered statistically significant. But statistical significance does not always equal clinical significance.

Confidence interval

A confidence interval shows the range of plausible values around an estimate, such as a hazard ratio. A wide confidence interval often means the data are immature, sample size is small or uncertainty is high.

Trial design terms

Control arm

The control arm is the comparison group in a clinical trial. It may receive placebo, standard of care, best available treatment or another active therapy.

BAT — best available treatment

Best available treatment, or BAT, is a type of control arm where investigators choose from allowed treatments based on the patient’s situation.

Event-driven trial

An event-driven trial ends or triggers analysis after a predefined number of events, such as deaths, progressions or relapses. A delayed event-driven trial can be encouraging, but in a blinded study it does not prove the experimental treatment is working.

Blinded data

In a blinded trial, patients, investigators, the company or some combination of these do not know which patients are in which treatment arm. Blinded pooled data can be easily overinterpreted.

Interim analysis and futility analysis

An interim analysis is a planned analysis before the final trial readout. A futility analysis asks whether the trial is unlikely to succeed if it continues.

Regulatory terms

BLA

A Biologics License Application is submitted to the FDA for approval of a biologic product, such as an antibody, cell therapy or certain immunotherapies.

PDUFA

A PDUFA date is the FDA’s target action date for deciding whether to approve a drug application.

CRL

A Complete Response Letter means the FDA has declined to approve the application in its current form. A CRL is usually a major negative catalyst.

Orphan Drug Designation

Orphan Drug Designation is granted for drugs targeting rare diseases. It can provide incentives such as market exclusivity, tax credits and fee waivers, but it does not guarantee approval.

Fast Track, Breakthrough Therapy and Priority Review

These FDA programs can speed development or review, but they do not guarantee approval.

Biotech stock terms

Dilution

Dilution happens when a company issues new shares, increasing the total share count. In biotech, dilution is common because companies often need to raise capital before they generate revenue.

ATM offering

An at-the-market offering, or ATM, allows a company to sell shares gradually into the market. ATMs can be useful financing tools, but they can also create ongoing dilution risk.

rNPV

Risk-adjusted net present value is a valuation method that discounts future cash flows by probability of success, time and risk.

How to use this glossary

The best way to use this glossary is alongside company press releases, SEC filings and trial readouts. When a biotech company reports a result, ask:

What was the endpoint?
Was the trial randomized?
Was the data blinded or unblinded?
How mature was the data?
Was the control arm strong?
Was the result statistically significant?
Was the result clinically meaningful?
How much dilution could occur before commercialization or a buyout?
Is the market pricing probability or certainty?

Understanding the terminology does not eliminate risk, but it helps investors ask better questions.